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It has been postulated that tumor cells expressing Fas
ligand (FasL) can evade immune surveillance by inducing
apoptosis in T cells expressing Fas. In this study, we investi-
gated FasL expression in 13 human hepatoma cell lines.
Strong FasL expression was detected by reverse transcription-
polymerase chain reaction or immunofluorescence in Hep
G2.2.15, in which the hepatitis-B-virus (HBV) genome was
transfected, and in SNU-354, which showed HBx transcripts.
To determine the biological activity of FasL, Hep G2.2.15 was
co-cultured with MOLT-4, T-cell-leukemia cells. Hep G2.2.15
induced apoptosis in MOLT-4 and this was inhibited by the
antagonistic anti-Fas antibody, ZB4. For further analysis of
the role of HBx in the induction of FasL, PLC/PRF/5 cells were
transfected transiently with the HBV genome, or HBx, or the
frameshift mutant of HBx. In PLC/PRF/5 cells transfected
with the HBV genome or HBx but not in cells transfected with
the frameshift mutant of HBx, FasL expression was detected.
Our data suggest that HBx plays a role in the induction of
FasL in hepatoma cells and in the escape from immune
surveillance. Int. J. Cancer 82:587–591, 1999.
r 1999 Wiley-Liss, Inc.
Fas ligand (FasL) belongs to the tumor necrosis factor (TNF)
family and induces apoptosis of Fas-bearing cells (Suda et al.,
1993). FasL is expressed mainly on the surface of activated T cells.
Fas–FasL interaction is one of the main effector mechanisms of
cytotoxic T lymphocytes (CTL) (Kagi et al., 1994) and is involved
in the activation-induced apoptosis of activated T cells (Dhein et
al., 1995). FasL is also expressed in immune-privileged sites, such
as eyes and testis, and it induces apoptosis of T cells (Griffith and
Ferguson, 1997). Therefore, FasL participates in the maintenance
of immune privilege status (Griffith and Ferguson, 1997). It has
been postulated that tumor cells expressing FasL could evade
immune surveillance by inducing apoptosis in tumor-infiltrating T
cells expressing Fas (Nagata, 1997; Walker et al., 1998). FasL was
detected in the sera of patients with malignant melanoma and
FasL-expressing melanoma cells induced apoptosis in Fas-bearing
cells (Hahne et al., 1996). In this study, delayed tumorigenesis was
shown by FasL-bearing melanoma cells in Fas-mutated lpr mice
(Hahne et al., 1996). Expression of FasL in colon cancer, lung
cancer, astrocytoma, pancreatic cancer and esophageal cancer has
also been reported (Bennett et al., 1998; Gratas et al., 1998;
O’Connell et al., 1996; Niehans et al., 1997; Saas et al., 1997;
Ungefroren et al., 1998). FasL-bearing astrocytoma efficiently
induced apoptosis of CD41 or CD81 tumor-infiltrating lympho-
cytes in a co-culture assay (Walker et al., 1997). These data indicate
that tumor cells expressing FasL induce apoptosis of tumor-
infiltrating T cells. In the liver, Fas and FasL may play an important
role in hepatocarcinogenesis (Strand et al., 1996). In hepatocellular
carcinomas (HCCs), Fas (which is highly expressed in normal
hepatocytes) was down-regulated (Shin et al., 1998), and FasL
(which is not expressed in normal hepatocytes) was expressed (Luo
et al., 1997; Strand et al., 1996). Moreover, FasL was expressed in
liver cirrhotic nodules (Luo et al., 1997).
Hepatitis B virus (HBV), especially the HBx gene product, is
suspected as being an oncogenic molecule responsible for hepato-
carcinogenesis, but the molecular mechanism is not clearly eluci-
dated. HBx protein interacts with wild-type p53 protein and
inhibits its function (Wang et al., 1994). Moreover, HBx protein
activates protein kinase C, Ras-Raf-MAP kinase cascade, AP-1 and
NF-kB (Henkler and Koshy, 1996) and HBx up-regulates various
host genes coding molecules of immunologic importance, such as
major histocompatibility complex (MHC) class I, MHC class II,
intracellular adhesion molecule (ICAM)-1 and TNF-a (Amaro et
al., 1994; Henkler and Koshy, 1996). However, the effect of HBx
on the expression of FasL, which belongs to the TNF family and
plays a role in the immune evasion of tumor cells, was not
determined.
In this study, we investigated the expression of FasL in human
hepatoma cell lines and evaluated the ability of FasL to induce
apoptosis of Fas-bearing cells. Furthermore, we investigated the
role of HBx in the induction of FasL in hepatoma cells to elucidate
the mechanism of FasL expression in human hepatoma cell lines.
MATERIAL AND METHODS
Cell lines and cell culture
Chang liver (ATCC CCL 13), SK-HEP-1 (ATCC HTB 52), Hep
G2 (ATCC HB 8065), Hep 3B (ATCC HB 8064), PLC/PRF/5
(ATCC CRL 8024), and MOLT-4 (ATCC CRL 1582), a T-cell
leukemia cell line, were obtained from the ATCC (Rockville, MD).
Hep G2.2.15 cells, a stable transfectant of HBV genome into Hep
G2 (Sells et al., 1987), were also included. SNU-182, SNU-354,
SNU-368, SNU-387, SNU-398, SNU-423, SNU-449 and SNU-475
were obtained from the Korean Cell Line Bank (Seoul, Republic of
Korea) (Park et al., 1995). It has been reported that SNU-354 and
SNU-368 expressed HBx mRNA (Park et al., 1995). All cell lines
were grown in modified Eagle’s medium (MEM) or RPMI 1640
containing 10% fetal calf serum (FCS; GIBCO BRL, Grand Island,
NY), 100 U/ml penicillin and 100 µg/ml streptomycin.
RNA isolation and reverse transcription-polymerase chain
reaction (RT-PCR)
Total RNA was isolated from cultured cells with RNeasy kit
(Qiagen, Santa Clarita, CA). cDNA was synthesized from 5 µg of
total RNA using 2 µg of random hexamer (Pharmacia, Uppsala,
Sweden), 1.25 mM dNTP (Boehringer, Mannheim, Germany) and
200 U of M-MLV reverse transcriptase (GIBCO BRL). PCR was
performed using 0.25 mM dNTP, 0.25 U of Taq polymerase
(Bioneer, Chongwon, Republic of Korea), 10 pmol of primer pairs
compatible with FasL or b-actin, and cDNA with thermal cycler
(Perkin Elmer, Branchburg, NJ). The following primer pairs were
used respectively: FasL: 58-ATGTTTCAGCTCTTCCACCTA-
CAGAAGGA-38 and 58-CAGAGAGAGCTCAGATAC GTTGAC-
38; b-actin: 58-CGTGGGCCGCCCTAGGCACCA-38 and 58-
TTGGCCTTAGGG TTCAGGGGGG-38. PCR cycling conditions
were: de-naturation at 94°C for 30 sec, annealing at 56°C for 30 sec
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and extension at 72°C for 1 min. Thirty-five cycles were carried out
for amplification of FasL and 22 cycles for b-actin.
RNase protection assay
RNase protection assay was performed with RiboQuant multi-
probe RNase protection assay kit (PharMingen, San Diego, CA)
according to the manufacturer’s instructions. 32P-labeled anti-sense
riboprobes compatible to apoptosis-related genes including FasL
and internal control (L32 and GAPDH) were synthesized with
hAPO-3 Human Apoptosis template set, 2.75 mM ATP, GTP, CTP,
100 µCi [a-32P]-UTP (3,000 Ci/mmol, NEN, Boston, MA) and 20
U T7 RNA polymerase. 32P-labeled anti-sense riboprobes were
hybridized with 10 µg of total RNA extracted from cultured cells at
56°C for 16 hr. After hybridization, 20 ng of RNase A and 50 U of
RNase T1 were added to digest unhybridized RNA and duplex
RNA hybrids were loaded onto 6% denaturing polyacrylamide gel
containing 8 M urea and autoradiography was performed.
Immunofluorescence staining for detection of FasL expression
Hep G2 or Hep G2.2.15 cells were fixed with acetone for 10 min
on a multi-spot microscope slide, then stained with 5 µg/ml NOK-1
anti-FasL antibody (PharMingen) in phosphate-buffered saline
(PBS) for 2 hr at room temperature. After 2 washes with PBS, the
cells were incubated with goat anti-mouse IgG fluorescein isothio-
cyanate (FITC)-conjugate (Cappel, West Chester, PA) for 1 hr at
room temperature in the dark. After 3 washes with PBS, cells were
observed by fluorescent microscopy.
Staining of apoptotic cells by annexin V
Hep G2.2.15 cells were cultured at 1 3 106 cells/well in 12 -well
plates. After overnight incubation, MOLT-4 cells were seeded at 2
3 105 cells/well into a Hep G2.2.15 growing well, and co-cultured
with Hep G2.2.15 for 30 hr. Then, non-adherent cells were
collected carefully and stained with propidium iodide and annexin
V-FITC conjugate (Clontech, Palo Alto, CA). Fluorescence inten-
sity was measured by FACStar (Becton Dickinson, Lincoln Park,
NJ). MOLT-4 cells were treated with antagonistic anti-Fas anti-
body, ZB4 (MBL, Watertown, MA) or agonistic anti-Fas antibody,
CH11 (MBL). MOLT-4 was pre-incubated with ZB4 at 500 ng/ml
for 1 hr and finally mixed into co-culture at 125 ng/ml of ZB4.
MOLT-4 was incubated with CH11 at 250 ng/ml for 30 hr.
Co-culture DNA fragmentation assay (JAM test)
MOLT-4 cells were incubated in media containing 10 µCi/ml
[3H]-thymidine (20 Ci/mmol, NEN) for 4 hr. After being washed
twice, labeled MOLT-4 cells were added at 2 3 104 cells/well into a
Hep G2.2.15 growing well at effector-cell-to-target-cell ratio (E:T
ratio) of 1:1, 1:2, and 1:5, and co-cultured with Hep G2.2.15 for 14
hr. DNA was harvested onto a glass fiber filter by cell harvester
(Skatron, Sterling, VA) and the radioactivity of intact DNA retained
on each filter was measured with a beta counter. Specific cell killing
was calculated using the following equation: % specific killing 5
(S 2 E)/S 3 100, where E (experimental) is counts per minute
(cpm) of retained DNA in the presence of effector cells, and S
(spontaneous) is cpm of retained DNA in the absence of effector
cells. Four independent experiments were carried out, each experi-
ment was performed in quintuplicate, and the median cpm was
used as the representative value.
Transient transfection of HBV genome or HBx
PLC/PRF/5 cells were cultured at 40% confluence in a 60-mm
culture dish. After overnight incubation, 10 µl of lipofectin
(GIBCO BRL) was mixed with 100 µl of OPTI-MEM (GIBCO
BRL), and incubated for 30 min at room temperature. Lipofectin-
OPTI-MEM mixture was mixed with 100 µl of OPTI-MEM
containing 2 µg of DNA construct. The DNA constructs used for
transfection were HBV genome, HBx under control of SV40
promoter (pSVX) and frameshift mutated HBx under control of
SV40 promoter (pSVXkB) (Spandau and Lee, 1988). After incuba-
tion for 10 min at room temperature, the mixture was added into
PLC/PRF/5 cells growing in a 60-mm culture dish. After 24 hr, the
medium was replaced with MEM containing 10% fetal bovine
serum, and cells were cultured for another 2 days, after which total
RNA was isolated.
RESULTS
Expression of FasL in human hepatoma cell lines
To verify the expression of FasL in human hepatoma cell lines,
RT-PCR was performed in 14 cell lines, i.e., 13 hepatoma cell lines
and 1 normal liver cell line. Strong FasL transcripts were detected
by RT-PCR in Hep G2.2.15 and SNU-354 (Fig. 1a). SNU-475
showed weak FasL transcripts, and the other cell lines including
Hep G2 showed very weak or no FasL transcripts. Hep G2.2.15 cell
line was a stable transfectant of HBV genome into Hep G2 and
produced infectious HBV virion particles (Sells et al., 1987), and
SNU-354 was one of the cell lines that showed HBx mRNA
transcripts (Park et al., 1995). With these results, we focused on
HepG2 and Hep G2.2.15 for further study. We could also detect
FasL mRNA transcripts in Hep G2.2.15, but not in Hep G2 by
RNase protection assay (Fig. 1b). To confirm FasL expression in
the protein level, we performed indirect-immunofluorescence stain-
ing for FasL. Strong FasL expression was detected in Hep G2.2.15,
but not in HepG2 (Fig. 1c).
FasL-expressing hepatoma cells induced apoptosis of Fas-bearing
cells
To investigate the functional activity inducing Fas-mediated
apoptosis by FasL expressed on Hep G2.2.15, Hep G2.2.15 cells
were co-cultured with Fas-bearing MOLT-4, a T-cell leukemic cell
line known to be sensitive to Fas-mediated apoptosis. MOLT-4
cells were co-cultured with Hep G2.2.15 for 30 hr. The non-
adherent cells were collected carefully and stained with propidium
iodide and annexin V. These cells began to show apoptotic features
(Fig. 2a). However, the antagonistic anti-Fas antibody, ZB4,
blocked apoptosis in our co-culture system. MOLT-4 cells cultured
without effectors or ZB4 anti-Fas antibody were not stained by
annexin V and propidium iodide; however, apoptosis was induced
in MOLT-4 when agonistic anti-Fas antibody, CH11, was added.
Furthermore, to confirm that FasL expressed on Hep G2.2.15
induces apoptosis of MOLT-4 via Fas/FasL pathway, we performed
a co-culture DNA fragmentation assay. When MOLT-4 cells were
co-cultured with Hep G2.2.15, MOLT-4 cells underwent apoptosis
(Fig. 2b) and this apoptosis was inhibited by ZB4 (Fig. 2c).
However, Hep G2 did not induce apoptosis of MOLT-4 and the
extent of apoptosis was not changed by ZB4.
Transfection with HBx and induction of FasL expression in
hepatoma cells
An effort was made to investigate the role of HBV or HBx in the
expression of FasL in hepatoma cell lines. For this purpose,
PLC/PRF/5 cells, which showed no FasL transcripts, were trans-
fected transiently with the HBV genome, or HBx, or frameshift
mutant of HBx and FasL transcripts were determined by RT-PCR.
We corroborated the expression of transfected genes in PLC/PRF/5
cells through RT-PCR of the HBx gene with RNase-free DNase-
treated total RNA of transfected cells. In the PLC/PRF/5 cells
transfected with HBV genome or HBx, but not in cells transfected
with the frameshift mutant of HBx, FasL mRNA transcripts were
detected (Fig. 3).
DISCUSSION
It has been suggested that tumor cells expressing FasL could
evade immune surveillance by inducing apoptosis in tumor-
infiltrating T cells expressing Fas (Nagata, 1997; Walker et al.,
1998), and this process was designated the Fas counterattack
(O’Connell et al., 1996). Expression of FasL has been reported in
many types of tumor including malignant melanoma, hepatoma,
colon cancer, lung cancer, astrocytoma, pancreatic cancer and
esophageal cancer (Bennett et al., 1998; Gratas et al., 1998; Hahne
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et al., 1996; Niehans et al., 1997; O’Connell et al., 1996; Saas et
al., 1997; Strand et al., 1996; Ungefroren et al., 1998).
In this study, we investigated the expression of FasL in human
hepatoma cell lines and evaluated the ability of FasL to induce
(a)
(b)
(c)
FIGURE 1 – Expression of FasL in a panel of human hepatoma cell
lines. (a) Detection of FasL mRNA transcript by reverse transcription-
polymerase chain reaction. Strong FasL transcripts were detected in
Hep G2.2.15 and SNU-354. (b) Detection of FasL-mRNA transcript by
RNase protection assay. FasL transcripts in Hep G2.2.15 were ob-
served. (c) Immunofluorescence staining with anti-FasL antibody
showed protein expression of FasL in Hep G2.2.15 (right), but not in
Hep G2 (left).
FIGURE 2 – Induction of apoptosis in MOLT-4 by Hep G2.2.15 via
Fas/FasL pathway. (a) MOLT-4 was treated with agonistic anti-Fas
antibody, CH11 or co-cultured with Hep G2.2.15 and stained with
annexin V. Apoptosis of MOLT-4 was induced by CH11 or Hep
G2.2.15, and Hep G2.2.15-induced apoptosis was blocked by ZB4. (b)
MOLT-4 cells labeled with [3H]-thymidine were co-cultured with Hep
G2 or Hep G2.2.15, and DNA fragmentation of MOLT-4 was measured
and calculated as a percentage of specific killing. Each dot and line
represent the mean and the standard error of the mean (SEM) of 3
independent experiments. E:T ratio represents ratio of effector cells to
target cells. (c) Antagonistic anti-Fas antibody, ZB4 was added into
co-culture system. Hep G2.2.15 induced-apoptosis was blocked by
ZB4. Each bar and line represent the mean and the SEM of 4
independent experiments.
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apoptosis of Fas-bearing cells. We also investigated the role of HBx
in the induction of FasL in hepatoma cells to elucidate the
mechanism of FasL expression in human hepatoma cell lines. As a
result, strong FasL expression was detected by RT-PCR in Hep
G2.2.15 in which HBV genome was transfected, and in SNU-354,
which showed HBx transcripts. The hypothesis that HBV gene
products including HBx may play an important role in the
expression of FasL was derived from these observations. FasL
expression was also confirmed by RNase protection assay or
immunofluorescence in Hep G2.2.15. To determine the biological
activity of FasL expressed on Hep G2.2.15 cells, Hep G2.2.15 was
co-cultured with MOLT-4, a T-cell-leukemia cell line. Hep G2.2.15
induced apoptosis in MOLT-4 and this was inhibited by the
antagonistic anti-Fas antibody, ZB4. These results imply that Hep
G2.2.15 induced apoptosis of MOLT-4 via Fas/FasL interaction. To
prove our hypothesis that HBx may play a role in induction of FasL
expression in hepatoma cell lines, PLC/PRF/5 cells were trans-
fected transiently with the HBV genome, or HBx, or the frameshift
mutant of HBx. In PLC/PRF/5 cells transfected with the HBV
genome or HBx but not in cells transfected with the frameshift
mutant of HBx, FasL expression was detected. These results
indicate that HBx might play an important role in activating the
expression of FasL in hepatoma cells. A similar result was reported
in the viral gene product of simian immunodeficiency virus. Nef of
simian immunodeficiency virus induced FasL in virus-infected
cells, and virus-infected cells induced apoptosis of CTLs to evade
the immune system (Xu et al., 1997).
It is known that HBx acts as a transcriptional transactivator and
up-regulates various host genes including, MHC class I, MHC
class II, ICAM-1 and TNF-a (Amaro et al., 1994; Henkler and
Koshy, 1996). HBx also activates various cellular transcription
factors such as AP-1 and NF-kB (Henkler and Koshy, 1996). In
addition, HBx may induce FasL expression through activation of
cellular transcription factors. Although there is no confirmative
report of transcription factor regulating FasL expression, the
enhancer region of the FasL gene has a putative binding site of
NF-kB (Takahashi et al., 1994) and the important role of NF-kB
has been reported in FasL gene activation (Kasibhatla et al., 1999;
Matsui et al., 1997). Because HBx activates NF-kB, it is possible
that HBx may induce FasL expression through NF-kB activation.
The FasL expression in hepatoma cells appears to be regulated by
multiple factors, because there was no strict correlation between
HBx expression and FasL expression in the hepatoma cell lines. It
is known that mRNA expression of HBx was observed not only in
SNU-354, but also in SNU-368 (Park et al., 1995). However,
SNU-368 did not express FasL. In opposition to SNU-368,
SNU-475, which did not show HBx transcripts (Park et al., 1995),
expressed weak FasL transcripts. These results imply that HBx is
not the only factor inducing FasL expression in hepatoma cell lines.
There have been many reports of factors capable of inducing FasL
expression on various tumor cells. They include cytokines (Ohtsuki
et al., 1997), anti-cancer chemotherapeutic drugs (Strand et al.,
1996), oxidative stress (Hug et al., 1997) and some viral gene
products (Chlichlia et al., 1997; Xu et al., 1997). It is unknown
whether these factors also induce FasL expression in various
hepatoma cell lines. More investigations are needed on the
regulation of FasL expression in hepatoma cells and transcription
factors regulating FasL expression. Moreover, the role of HBx in
transcription regulation of the FasL gene should be examined
further regarding its mechanism and responsible transcription
factor.
In conclusion, we propose that HBx plays a role in the induction
of FasL in hepatoma cells and in the escape from immune
surveillance through the induction of apoptosis of activated T cells
expressing Fas.
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